NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

Gerhardt Attard, M.D., Ph.D., from University College London, and colleagues conducted a double-blind trial that evaluated combining niraparib with AAP versus placebo and AAP in mCSPC with HRR gene ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

Orphan Drug Designation The purpose of the Orphan Product program is to support the development and evaluation of new treatments for rare diseases. FDA grants Orphan Drug designation to ...

The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor ...

A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

Stanford Medicine researchers invent an electromagnetic device that can gently sort different types of cells by levitating ...